Life
Briefing: STAT+: Pharmalittle: We’re reading about telehealth prescribers, a Lilly push against compounding, and more
Strategic angle: Medical groups affiliated with telehealth companies the FDA warned about marketing of compounded weight loss drugs may be under the microscope, too
editorial-staff
1 min read
Updated about 1 month ago
Recent developments indicate that telehealth companies may face increased regulatory scrutiny from the FDA, particularly concerning their marketing practices for compounded weight loss drugs.
Medical groups associated with these telehealth providers are now reportedly under examination, as the FDA's concerns could lead to broader implications for telehealth infrastructure and compliance standards.
This situation underscores the need for telehealth operators to reassess their marketing strategies and ensure adherence to regulatory guidelines to mitigate potential risks.